BeiGene Ltd ADR Stock
BeiGene Ltd ADR Stock
There is an upward development for BeiGene Ltd ADR compared to yesterday, with an increase of €3.00 (1.890%).
With 9 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 241 € shows a very positive potential of 50.63% compared to the current price of 160.0 € for BeiGene Ltd ADR.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for BeiGene Ltd ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of BeiGene Ltd ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of BeiGene Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| BeiGene Ltd ADR | 1.890% | 7.383% | 31.148% | -23.810% | -3.030% | -43.262% | - |
| Evolus Inc | -1.650% | 2.586% | 12.264% | 32.222% | 31.492% | 59.732% | - |
| Ardelyx Inc. | -1.500% | -0.973% | 16.896% | 117.256% | 23.287% | 25.018% | - |
| Salarius Pharmaceuticals Inc. | 0.960% | 1.449% | 0.000% | -63.478% | -24.324% | -98.369% | -99.992% |
Comments
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $236.00 to $254.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $235.00 to $236.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $184.00 to $186.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for BGNE provided by MarketBeat